Q-omics provides the consensus-scored GAPDHP62 profile across patient tissues and cancer cell-line models. GAPDHP62 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, GAPDHP62 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, GAPDHP62 RNA expression shows 16,927 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight KIRP, KIRC, and DLBC as cancer lineages where GAPDHP62 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GAPDHP62 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GAPDHP62 survival associations across molecular data types. GAPDHP62 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GAPDHP62 RNA expression–survival associations across cancer types. High GAPDHP62 expression shows unfavorable associations in KIRP, UVM, KIRC and KICH, but favorable associations in UCS and BLCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for GAPDHP62 RNA expression.
This table summarizes GAPDHP62 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GAPDHP62. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GAPDHP62 shows higher tumor expression in KIRC, HNSC, COAD, LUAD, LUSC and BLCA. The KIRC box plot shows higher GAPDHP62 RNA expression in tumor versus normal tissue (log2 FC = +0.105, t-test p < 0.001).
This table shows molecular features associated with GAPDHP62 in patient tissues and cancer cell lines. In patient samples, GAPDHP62 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
